Stockreport

Jaguar Health outlines dual NDA filing targets for late 2026 as clinical catalysts converge [Seeking Alpha]

Jaguar Health, Inc.  (JAGX) 
US:NASDAQ Investor Relations: jaguarhealth.gcs-web.com/investor-overview
PDF Lisa Conte, Founder, CEO, President & Director, highlighted that combined net third quarter 2025 revenue of approximately $3.1 million for prescription and nonprescript [Read more]